Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 44th Annual Conference. Myriad’s MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen and Foresight® Carrier Screen are among the products included in the new studies to be shared.
“The data we’re presenting at NSGC demonstrates our ongoing commitment to advancing scientific research aimed at improving patient outcomes and delivering innovative products that provide timely, data-driven, actionable insights to inform more personalized patient care,” said Katie Johansen Taber, PhD, Vice President, Clinical Product Research & Partnerships, Myriad Genetics. “We’re excited to share this research with the genetic counseling community and to continue collaborating to help make genetic testing more accessible for all patients.”
Myriad’s latest innovations and support services will be on display at booth #317 and through a series of poster presentations throughout the conference.
Myriad’s presentation schedule
Friday, Nov. 7, 2025, at 5:15pm PT
- Poster #CAN103: RNA analysis from residual blood aids the interpretation of Variant of Uncertain Significance (VUS) identified in individuals undergoing hereditary cancer genetic testing
- Poster #GENT253: Fetal fraction amplification yields sufficient fetal fraction to enable cfDNA screening with a low screen-failure rate between 8-10 weeks gestation
- Poster #PRE365: Provider & patient uptake of prenatal cfDNA screening at an earlier gestational age
- Poster #PRE363: Prenatal cell-free DNA screening helps uncover maternal colorectal cancer: a case study
- Poster #GENT245: High-throughput, automated detection of FXN repeat expansions using repeat primed PCR followed by capillary electrophoresis
- Poster #PRE385: From concept to care: the evolution of a genetic screening report through clinical and design collaboration
- Poster #CAN083: The spectrum of germline hereditary cancer mutations within a laboratory-based research registry
- Poster #EDU161: Shaping the future: Evolving a field-based laboratory rotation to meet the needs of genetic counseling students
- Poster #EDU159: Genetic counseling student interest in GC roles in an industry rotation setting
Saturday, Nov. 8, 2025, at 5:00pm PT
- Poster #ASD018: Leveraging a longitudinal genomics platform to recontact patients eligible for Hereditary Cancer Genetic Testing
- Poster #PRO394: Professional development for seasoned genetic counselors: Moving from clinical expertise to leadership excellence
For more information about Myriad’s presence at NSGC, please visit: . Updates will also be shared across Myriad’s LinkedIn and X channels throughout the conference.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit .
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the company’s ongoing commitment to scientific research and collaborations aimed at improving patient outcomes and expanding access to genetic testing. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
Media Contact
Kate Schraml
(224) 875-4493
